ÂÜÀòÂÒÂ×

Mark Eggink is a Principal Scientist and Group Lead for NBE method development in Phys/Chem at Byondis since May 2010, focusing on assay development and validation of new biological entities, including monoclonal antibodies and antibody drug conjugates. Prior experience includes roles as Lead Scientist/Project Leader in Bioanalytics at Synthon from October 2008 to May 2010, and as a Researcher in Bioanalytics at VU University Amsterdam from September 2004 to August 2008, where Mark Eggink developed multidimensional chromatographic techniques and mass spectrometry methods for biomarker detection. Mark Eggink holds an MSc in Pharmaceutical Sciences from Vrije Universiteit Amsterdam and an engineering degree in Analytical Chemistry from Saxion University of Applied Sciences.